Bio-Thera Solutions Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bio-Thera Solutions Ltd.
Biogen and Bio-Thera have revealed positive Phase III data for their proposed tocilizumab biosimilar rival to Actemra/RoAcetmra.
Bio-Thera Solutions had been hoping to become the first Chinese biosimilars developer to win an FDA approval, for its BAT1706 bevacizumab candidate. However, the announced FDA action date for the application has come and gone with no word from the company or regulator.
After the anti-PD-1/L1 antibody and cell therapy rush, antibody-drug conjugates are quickly gaining attention in China as new technologies and deal-making activity heats up, but one first mover warns of potential over-crowding.
Deal-happy Bio-Thera Solutions has signed another license and supply agreement, agreeing to out-license its BAT2206 biosimilar ustekinumab candidate in Russia and other CIS countries to local player Pharmapark.
- Generic Drugs
- Drug Discovery Tools
- Other Names / Subsidiaries
- Biotech Biopharmaceutical Co., Ltd.